The IGF System and Aging
-
By
-
Cheryl A Conover
-
Claus Oxvig
-
October 17, 2024
-
Clinical Scorecard: The Role of the IGF System in the Aging Process
At a Glance
| Category | Detail |
|---|
| Condition | Aging and age-related diseases |
| Key Mechanisms | IGF signaling involving receptors, ligands, binding proteins, proteinases, and endogenous inhibitors modulating cellular senescence and tissue function |
| Target Population | Humans and model organisms relevant to aging research |
| Care Setting | Research and clinical settings focusing on aging and age-related diseases |
Key Highlights
- IGF system components are evolutionarily conserved and regulate fundamental aging processes.
- IGF-IR mediates cell survival, mitogenesis, and differentiated functions via intracellular signaling pathways.
- Proteolytic regulation of IGF binding proteins by PAPP-A and PAPP-A2 modulates local IGF bioavailability and activity.
Guideline-Based Recommendations
Diagnosis
- Consider IGF system component expression and activity in studies of aging and age-related diseases.
Management
- Target IGF system components, such as PAPP-A and IGF-IR, as potential therapeutic avenues to promote healthy aging.
Monitoring & Follow-up
- Monitor IGF ligand levels, IGFBP proteolysis, and receptor activation status in relevant tissues and circulation.
Risks
- Dysregulated IGF signaling may contribute to age-related diseases including pulmonary fibrosis, Alzheimer disease, and macular degeneration.
Patient & Prescribing Data
Individuals with age-related diseases or at risk of aging-associated pathologies
Modulation of IGF system activity through inhibition or enhancement of specific components may influence disease progression and healthy aging.
Clinical Best Practices
- Evaluate the balance of IGF ligands, receptors, and binding proteins in the context of patient age and disease state.
- Consider the role of IGFBP proteases (PAPP-A, PAPP-A2) and their inhibitors (STC1, STC2) in regulating IGF bioactivity.
- Integrate knowledge of IGF system complexity when designing interventions targeting aging and related diseases.
References
